



CERTIFICATE OF MAILING

I hereby certify that this paper and every  
page referred to therein as being enclosed  
has been deposited with the U.S. Postal  
Service as first class mail, postage prepaid,  
in an envelope addressed to: Commissioner of  
Patents and Trademarks, Washington, D.C. 20231,  
on December 16, 1996 (Date of Deposit)

12/16/96 A. Stanline  
Date Name

RECEIVED

JAN 8 1997

GROUP 1800

1010/16104/US4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Howard L. WEINER et al.

Serial No.: 08/279,275

Group Art Unit: 1816

Filed : July 22, 1994

Examiner: P. Achutamurthy

For : **TREATMENT OF AUTOIMMUNE DISEASE BY ORAL ADMINISTRA-  
TION OF AUTOANTIGENS**

Honorable Commissioner of  
Patents and Trademarks  
Washington, D.C. 20231

**CERTIFICATION UNDER 37 C.F.R. 1.97(e)(1)**  
**ACCOMPANYING INFORMATION DISCLOSURE STATEMENT**

Sir:

I hereby certify, that each item of information contained in the Information  
Disclosure Statement was cited in a communication from a foreign patent office in a coun-  
terpart foreign application not more than three months prior to the filing of the statement.

Respectfully submitted,

*Seth H. Jacobs*  
Seth H. Jacobs  
Registration No. 32,140  
Agent for Applicant(s)

DARBY & DARBY P.C.  
805 Third Avenue  
New York, New York 10022  
(212) 527-7700

M:\1010\16104\PS0480

#45

G.M.

1-30-97

w/Attach

CERTIFICATE OF MAILING

I hereby certify that this paper and every paper referred to therein as being enclosed is being deposited with the U.S. Postal Service as first class mail, postage prepaid, in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231, on December 16, 1996 (Date of Deposit)



12/16/96 H. L. Weiner  
Date Name

1010/16104 US4

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:

Howard L. WEINER et al.

Serial No: 08/279,275                      Group Art Unit: 1816  
Filed: July 22, 1994                      Examiner: P. Achutamurthy  
For: **TREATMENT OF AUTOIMMUNE DISEASE BY ORAL  
ADMINISTRATION OF AUTOANTIGENS**

-----  
Honorable Commissioner of  
Patents and Trademarks  
Washington, D.C. 20231

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Sir:

In order to comply with discretionary regulations 37 CFR §§ 1.97 and 1.98, attached hereto is Form PTO-1449, and copies<sup>1</sup> of the documents listed thereon. These

---

<sup>1</sup>To the extent that a document is listed and no copy of same is attached, then such document is not at the present time available to the undersigned or is available in the file of a parent application. If a listed document is not in the English language and an English translation is readily available, such translation is also attached; if translation is not attached it is not readily available to the undersigned. If a foreign language patent document is cited, and an English language equivalent is known to the undersigned, then such equivalent patent is also cited on the attached form along with the corresponding foreign language patent and a connecting arrow indicated

documents contain information which the Examiner may consider to be important in deciding whether to allow the present application to issue as a patent and which were cited with respect to European Patent Number 0 359 783 B1. A certification under 37 CFR § 1.97 (e) accompanies this paper. This Information Disclosure Statement should be considered by the office under 37 CFR § 1.97 (c).

In accordance with MPEP Sections 609 and 707.05(b), it is requested that each document cited (including any cited in applicant's specification which is not repeated on the attached Form PTO-1449) be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing on Form PTO-1449. Such initialing is requested even if the Examiner does not consider a cited document to be sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application.

The present Disclosure Statement is being submitted in compliance with 37 CFR 1.56 insofar as an Examiner might consider any of the cited documents important in deciding whether to allow the application to issue as a patent, but the citation of each document is not to be construed as an admission that such document is necessarily relevant or prior art. No representation is intended that the cited documents represent the results of a complete search, and it is anticipated that the Examiner, in the normal course of examination, will make an independent search and will determine the best prior art consistent


---

therebetween; if no such English language equivalent is cited, then none is known to the undersigned.

with 37 CFR 1.104(a) and 1.106(b) and, in the course of each search, will review for relevance every document cited on the attached form even if not initialed.

Early and favorable consideration is earnestly solicited.

Respectfully submitted,

  
\_\_\_\_\_  
Seth H. Jacobs  
Registration No. 32,140  
Attorney for Applicant(s)

DARBY & DARBY P.C.  
805 Third Avenue  
New York, N.Y. 10022  
(212) 527-7700